Basilea News http://www.basilea.com/ Basilea News en Sun, 27 May 2018 07:18:13 +0200 Sun, 27 May 2018 07:18:13 +0200 Chameleon CMS webmaster@basila.com (Webmaster Webmaster) webmaster@basila.com (Webmaster Webmaster) <![CDATA[Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Saudi Arabia by Hikma Pharmaceuticals LLC]]> http://www.basilea.com/News-and-Media/Basilea-reports-launch-of-antibiotic-Zevtera-ceftobiprole-in-Saudi-Arabia-by-Hikma-Pharmaceuticals-LLC/09d418d8-a71f-f97d-f4d6-838bab2e8eea Tue, 15 May 2018 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-reports-launch-of-antibiotic-Zevtera-ceftobiprole-in-Saudi-Arabia-by-Hikma-Pharmaceuticals-LLC/09d418d8-a71f-f97d-f4d6-838bab2e8eea <![CDATA[Basilea announces appointment of Chief Technology Officer and appointment of Head of Global Quality Management]]> http://www.basilea.com/News-and-Media/Basilea-announces-appointment-of-Chief-Technology-Officer-and-appointment-of-Head-of-Global-Quality-Management/87e80d92-6164-c270-936d-152c6b764506
  • Dr. Gerrit Hauck appointed as Chief Technology Officer, succeeding Dr. Günter Ditzinger who will take on new responsibilities at Basilea
  • Dr. Anne Stehlin succeeding Dr. Josef Künzle as Head of Global Quality Management upon his retirement
  • ]]>
    Fri, 27 Apr 2018 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-announces-appointment-of-Chief-Technology-Officer-and-appointment-of-Head-of-Global-Quality-Management/87e80d92-6164-c270-936d-152c6b764506
    <![CDATA[Basilea reports presentations of isavuconazole and ceftobiprole data at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)]]> http://www.basilea.com/News-and-Media/Basilea-reports-presentations-of-isavuconazole-and-ceftobiprole-data-at-European-Congress-of-Clinical-Microbiology-and-Infectious-Diseases-ECCMID/e02884b0-cea0-1aec-012d-ee5f888dbab5 Fri, 20 Apr 2018 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-reports-presentations-of-isavuconazole-and-ceftobiprole-data-at-European-Congress-of-Clinical-Microbiology-and-Infectious-Diseases-ECCMID/e02884b0-cea0-1aec-012d-ee5f888dbab5 <![CDATA[Basilea shareholders approve all proposals of the Board of Directors at the Annual General Meeting of Shareholders]]> http://www.basilea.com/News-and-Media/Basilea-shareholders-approve-all-proposals-of-the-Board-of-Directors-at-the-Annual-General-Meeting-of-Shareholders/17aedcb9-9780-d610-1bb3-4284de81f7ca Wed, 18 Apr 2018 18:06:16 +0200 http://www.basilea.com/News-and-Media/Basilea-shareholders-approve-all-proposals-of-the-Board-of-Directors-at-the-Annual-General-Meeting-of-Shareholders/17aedcb9-9780-d610-1bb3-4284de81f7ca <![CDATA[Basilea reports start of clinical phase 3 study in Japan by Asahi Kasei Pharma with antifungal isavuconazole]]> http://www.basilea.com/News-and-Media/Basilea-reports-start-of-clinical-phase-3-study-in-Japan-by-Asahi-Kasei-Pharma-with-antifungal-isavuconazole/f0e6a36e-abd4-35f0-84c7-a4bcb9a4f81d Wed, 18 Apr 2018 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-reports-start-of-clinical-phase-3-study-in-Japan-by-Asahi-Kasei-Pharma-with-antifungal-isavuconazole/f0e6a36e-abd4-35f0-84c7-a4bcb9a4f81d <![CDATA[Basilea licenses late-stage oncology drug candidate derazantinib from ArQule]]> http://www.basilea.com/News-and-Media/Basilea-licenses-late-stage-oncology-drug-candidate-derazantinib-from-ArQule/fa686b42-543a-2e06-5ae4-0727525e6197 Tue, 17 Apr 2018 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-licenses-late-stage-oncology-drug-candidate-derazantinib-from-ArQule/fa686b42-543a-2e06-5ae4-0727525e6197 <![CDATA[Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Canada by Avir Pharma]]> http://www.basilea.com/News-and-Media/Basilea-reports-launch-of-antibiotic-Zevtera-ceftobiprole-in-Canada-by-Avir-Pharma/6bc30897-7515-a172-28b4-d224c4aefd09 Mon, 09 Apr 2018 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-reports-launch-of-antibiotic-Zevtera-ceftobiprole-in-Canada-by-Avir-Pharma/6bc30897-7515-a172-28b4-d224c4aefd09 <![CDATA[Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Argentina by Grupo Biotoscana]]> http://www.basilea.com/News-and-Media/Basilea-reports-launch-of-antibiotic-Zevtera-ceftobiprole-in-Argentina-by-Grupo-Biotoscana/72ea7d67-70f0-6283-4a5c-e4746fc6b328
  • First launch in Latin America
  • ]]>
    Tue, 06 Mar 2018 07:15:00 +0100 http://www.basilea.com/News-and-Media/Basilea-reports-launch-of-antibiotic-Zevtera-ceftobiprole-in-Argentina-by-Grupo-Biotoscana/72ea7d67-70f0-6283-4a5c-e4746fc6b328
    <![CDATA[Basilea names Adesh Kaul as new member of its Management Committee]]> http://www.basilea.com/News-and-Media/Basilea-names-Adesh-Kaul-as-new-member-of-its-Management-Committee/f89d646f-c6c2-4445-28b9-ab75378e2cd2 Thu, 01 Mar 2018 07:15:00 +0100 http://www.basilea.com/News-and-Media/Basilea-names-Adesh-Kaul-as-new-member-of-its-Management-Committee/f89d646f-c6c2-4445-28b9-ab75378e2cd2 <![CDATA[Basilea reports significantly improved financial results in 2017]]> http://www.basilea.com/News-and-Media/Basilea-reports-significantly-improved-financial-results-in-2017/215a1b7f-2539-a3d7-b94a-123964101265
  • 54% increase in total revenue, amounting to CHF 101.5 million
  • Operating loss reduced by 68% to CHF 14.1 million
  • Cash position as of year-end 2017 increased to CHF 310.7 million
  • License and distribution agreements in 2017 for Cresemba® and Zevtera® cover more than 100 countries with CHF 80 million in upfront payments and up to USD 1.1 billion potential milestone payments
  • ]]>
    Tue, 27 Feb 2018 07:15:00 +0100 http://www.basilea.com/News-and-Media/Basilea-reports-significantly-improved-financial-results-in-2017/215a1b7f-2539-a3d7-b94a-123964101265